Fig. 4

The effect of gmfg deficiency on PLM formation, DA specification, and EC proliferation or apoptosis. a Expression of the PLM marker fli1a in embryos injected with control MO, gmfg-atgMO, and gmfg-spMO analyzed by WISH at 12 hpf. b and c Expression of the DA-specific markers ephrinB2a and dlc in control and gmfg morphants analyzed by WISH at 24 (b) and 28 hpf (c). d TUNEL staining in fli1a:eGFP transgenic embryos injected with control MO, gmfg-atgMO, and gmfg-spMO at 26 and 32 hpf. White dashed lines indicate blood vessels and white arrowheads indicate the apoptosis of fli1a + cells. e Quantification of apoptotic fli1a + TUNEL + cells in (d). Bars represent mean ± SD of control (n = 18), gmfg-atgMO (n = 17), and gmfg-spMO (n = 18). ns, not significant. f PH3 staining in fli1a:eGFP transgenic embryos injected with control MO, gmfg-atgMO, and gmfg-spMO at 26 and 36 hpf. White dashed lines indicate blood vessels and white arrowheads indicate proliferative fli1a + cells. g Quantification of proliferative fli1a + pH3 + cells in (f), Bars represent mean ± SD of control (n = 18), gmfg-atgMO (n = 17), and gmfg-spMO (n = 18). ns, not significant. h Expression of runx1 and cmyb in the AGM in p53 mutant injected with control MO, gmfg-atgMO, and gmfg-spMO at 26 (left) and 36 hpf (right). The red arrowheads mark HSPCs in the AGM. Numbers at the lower right corner of the picture represent embryos with displayed phenotype/whole embryos. All scale bars, 100 µm